Detalhe da pesquisa
1.
Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patients.
Eur J Haematol;
107(5): 566-572, 2021 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34297879
2.
Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
Chemotherapy;
63(6): 340-344, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30965327
3.
UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia.
Am J Hematol;
94(11): E283-E285, 2019 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31364196
4.
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial.
Blood Adv;
7(19): 5996-6004, 2023 Oct 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37450382
5.
Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience.
Front Oncol;
12: 795955, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35392224